内侧轴心型TKA不置换髌骨时生存率低于保留交叉韧带型
基于澳大利亚和挪威关节登记数据(2005-2017年),比较内侧轴心型与保留交叉韧带型TKA(均不置换髌骨、固定平台、骨水泥胫骨)的生存率。澳大利亚数据显示内侧轴心型翻修风险增高(HR 1.4),挪威无差异;不同品牌表现不一,Advance II MP和GMK Sphere生存率较差。
要点
- 内侧轴心型TKA整体翻修风险高于保留交叉韧带型(澳大利亚HR 1.4)。
- Advance II MP和GMK Sphere翻修风险增高,MRK、SAIPH、Evolution MP无差异。
- 澳大利亚翻修主因为感染、单纯疼痛、髌骨侵蚀;挪威为松动/骨溶解、不稳。
核心结论
- 不置换髌骨的内侧轴心型TKA整体翻修率高于保留交叉韧带型固定平台对照。
- 按品牌分析,Advance II MP和GMK Sphere生存率较差,MRK、SAIPH和Evolution MP与对照无差异。
研究设计与样本
- 基于澳大利亚骨科协会国家关节置换登记处和挪威关节置换登记处2005年至2017年底的数据进行回顾性登记研究。
- 内侧轴心型TKA共6310例(澳大利亚6012例,占无髌骨置换骨水泥/混合TKA的9%;挪威298例,占1%)。
- 对照组为三种最常用保留交叉韧带型TKA共70870例(澳大利亚54554例,挪威16316例)。
- 所有TKA均使用固定平台骨水泥胫骨组件且不置换髌骨,采用Kaplan-Meier生存分析和Cox回归计算风险比(HR),校正年龄、性别和术前诊断。
主要发现
- 澳大利亚内侧轴心型较保留交叉韧带型翻修风险增高(HR 1.4 [95% CI 1.2 to 1.7];p < 0.001),挪威无差异(HR 1.5 [95% CI 0.9 to 2.4];p = 0.1)。
- 澳大利亚Advance® II MP翻修风险增高(HR 1.7 [95% CI 1.2 to 2.6];p = 0.004),GMK® Sphere增高(HR 2.0 [95% CI 1.5 to 2.6];p < 0.001)。
- 澳大利亚MRK(HR 0.7 [95% CI 0.4 to 1.5];p = 0.4)、Evolution® MP(HR 1.4 [95% CI 1.0 to 1.9];p = 0.06)、SAIPH®(HR 0.9 [95% CI 0.5 to 1.5];p = 0.7)与对照无差异。
- 澳大利亚内侧轴心型翻修原因占比:感染27%、单纯疼痛19%、髌骨侵蚀13%、松动/骨溶解12%。
- 挪威内侧轴心型翻修原因占比:松动/骨溶解28%、不稳28%、对线不良11%、单纯疼痛11%。
关键数值与推荐
- 澳大利亚内侧轴心型翻修风险HR 1.4(95% CI 1.2 to 1.7;p < 0.001)。
- Advance II MP翻修风险HR 1.7(95% CI 1.2 to 2.6;p = 0.004),GMK Sphere HR 2.0(95% CI 1.5 to 2.6;p < 0.001)。
- 挪威内侧轴心型翻修风险HR 1.5(95% CI 0.9 to 2.4;p = 0.1),无统计学差异。
临床怎么用
- 选择内侧轴心型TKA且不置换髌骨时,应告知患者其翻修风险可能高于保留交叉韧带型设计。
- 不同品牌内侧轴心型生存率存在差异,Advance II MP和GMK Sphere翻修风险较高。
- 术后随访需关注感染、疼痛、髌骨侵蚀、松动/骨溶解及不稳等翻修原因。
局限性
- 部分内侧轴心型植入物在本研究中随访时间较短。
- 需更长期随访的登记研究进一步验证。
- 证据等级为III级,治疗性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The medial pivot TKA design was introduced in the 1990s. These are fixed-bearing, medial-conforming implants with virtually no translation in the medial part of the knee, in contrast to the flat lateral part of the insert allowing for translation similar to the native knee during flexion and extension. Most primary TKAs performed in Norway and Australia are cruciate-retaining. All of the medial pivot implants in our study are cruciate-sacrificing but without a post-cam mechanism. The medial pivot implant design was developed to more closely mimic native knee motion, in the hope of improving function, and not primarily as a more constrained knee for difficult cases. In the past 10 to 12 years, a second-generation medial-pivot design has emerged, but there are no larger registry studies on the survival of these implants. Both cruciate-retaining and medial pivot designs are reported in the Australian and Norwegian registries, allowing for large-scale, comparative survivorship studies. QUESTIONS/PURPOSES: (1) Is there any difference in survival between the medial pivot design and the three most commonly used cruciate-retaining TKA designs? (2) Is there any difference in survival among the different medial pivot implant designs? (3) What are the main indications for revision of medial pivot TKAs? METHODS: Registry data from the Australian Orthopaedic Association National Joint Replacement Registry and Norwegian Arthroplasty Register from 2005 until the end of 2017 were used to compare the five different brands of medial pivot TKA designs (total primary TKAs assessed: 6310). In Australia, the study group of medial pivot implants represented 9% (6012 of 72,477) of the total number of cemented/hybrid TKAs without patellar resurfacing; 345 had cementless femoral components. In Norway, the study group represented 1% (298 of 47,820) of the total number of TKAs with cemented tibias without patellar resurfacing; all had cemented femoral components. The control group consisted of the three most commonly used cruciate-retaining TKA designs (n = 70,870; Australia n = 54,554; Norway n = 16,316). All TKAs used a fixed-bearing, cemented tibial component and did not involve patella resurfacing. Kaplan-Meier survival analysis was assessed to estimate survivorship. We compared the groups by calculating the hazard ratios (HR) using Cox regression adjusted for age, gender and preoperative diagnosis with 95% CI. To answer our third question, we calculated the percentage of each revision indication from the total number of revisions in each group, and used a Cox regression analysis to compare revision causes and HRs. Analyses were performed separately by each registry. Accounting for competing risks (Fine and Gray) did not alter our findings []. RESULTS: After controlling for potential confounding variables such as gender, age and preoperative diagnosis, we found an increased revision risk for the medial pivot compared with cruciate-retaining TKA designs in Australia (HR 1.4 [95% CI 1.2 to 1.7]; p < 0.001), but not in Norway (HR 1.5 [95% CI 0.9 to 2.4]; p = 0.1). Two brands of the medial pivot design reported to the AOANJRR showed an increased risk of revision compared with cruciate-retaining designs: the Advance® II MP (HR 1.7 [95% CI 1.2 to 2.6]; p = 0.004) and the GMK® Sphere (HR 2.0 [95% CI 1.5 to 2.6]; p < 0.001), whereas the MRK (HR 0.7 [95% CI 0.4 to 1.5]; p = 0.4), the Evolution® MP (HR 1.4 [95% CI 1.0 to 1.9]; p = 0.06) and the SAIPH® (HR 0.9 [95% CI 0.5 to 1.5]; p = 0.7) showed no difference. The most common reasons for revision of medial pivot implants in Australia were infection (27%), pain alone (19%), patellar erosion (13%), loosening/lysis (12%); in Norway the primary indications were loosening/lysis (28%), instability (28%), malalignment (11%) and pain alone (11%). CONCLUSIONS: The medial pivot TKA design as a group had a higher revision rate than cruciate-retaining fixed-bearing controls in TKA performed without patellar component resurfacing. By brand, the Advance II MP and the GMK Sphere had inferior survivorship, whereas the MRK, the SAIPH and the Evolution MP had no differences in survivorship compared with cruciate-retaining controls. In Australia, TKAs with the medial pivot design without patella resurfacing had a higher rate of revisions for instability, malalignment, and patella erosion. In Norway, there was an increased risk of revision for lysis and loosening compared with the cruciate-retaining design. Several of these implants had short follow-up in this study. Further registry studies with longer follow up are therefore necessary. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Øhrn FD, Gøthesen Ø, Låstad Lygre SH, et al. Decreased Survival of Medial Pivot Designs Compared with Cruciate-retaining Designs in TKA Without Patellar Resurfacing. Clin Orthop Relat Res. 2020. PMID: 31977446. doi:10.1097/CORR.0000000000001120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。